Complex link between diabetes drugs and pancreatic cancer risk

Home Research Strategic Research Program News Complex link between diabetes drugs and pancreatic cancer risk

Research in the News

Complex link between diabetes drugs and pancreatic cancer risk

Diabetes is considered both a risk factor and a symptom of pancreatic cancer. A recent study looked at the association between several diabetes drugs and the risk of pancreatic cancer. The authors concluded that taking the diabetes drug metformin resulted in a small but statistically significant decrease in the risk of being diagnosed with pancreatic cancer for women, but not for men, a result that was described as “unexpected” since there is no known biological basis that would explain this difference. Other diabetes drugs, however, like sulfonylureas and the administration of insulin itself, led to a slightly increased risk of pancreatic cancer in both men and women. This result was consistent with other studies, and the difference between metformin and these other diabetes drugs is believed to be due to a difference in the way they act to treat diabetes.

The results were published in the January 31, 2012 issue of American Journal of Gastroenterology. The analyses primarily took place in the laboratory of Christoph Meier, PhD at the University Hospital Basel in Switzerland.

Dr. Meier and colleagues utilized data from the General Practice Research Database (GPRD). The GPRD is a large database from the United Kingdom, including anonymous medical information (demographics, therapy, treatment response, etc) on over eight million individuals. The investigators identified individuals who were first diagnosed with pancreatic cancer between 1995 and 2009 and were under the age of 90, and found 2,763 patients. For each patient, they selected six control individuals (people who had not been diagnosed with pancreatic cancer) with matching characteristics like age and gender, to conduct comparisons.

Further experiments will be necessary to understand the complex relationship between diabetes, diabetes drugs, and pancreatic cancer risk.

For more information about this study or other questions about pancreatic cancer risk factors, diagnosis, or treatment, please contact a Pancreatic Cancer Action Network Patient and Liaison Services (PALS) Associate toll-free at 877-272-6226 or email PALS Associates are available M-F 7am-5pm Pacific Time.

Please click here for the scientific abstract.

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved.

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision PromiseSM and Demand Better For Patients. For Survival.SM are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.